Trial Outcomes & Findings for The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia (NCT NCT03735433)
NCT ID: NCT03735433
Last Updated: 2024-04-29
Results Overview
by acog definitions
TERMINATED
PHASE4
152 participants
Through study completion, an average for 10 months
2024-04-29
Participant Flow
Participant milestones
| Measure |
81 mg Daily Aspirin Dose
obese women \>30 BMI at risk for preeclampsia will receive recommended 81mg ASA
|
162mg Daily Aspirin Dose
obese women \>30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA
162mg aspirin dose: 2 pills of 81mg aspirin
|
|---|---|---|
|
Overall Study
STARTED
|
76
|
76
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
76
|
76
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: Through study completion, an average for 10 monthsPopulation: Study outcomes were not collected as no participants completed either 81 mg or 162 mg aspirin dose. Participation was terminated before completion of the study.
by acog definitions
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Through study completion, an average for 10 monthsPopulation: Study outcomes were not collected as no participants completed either 81 mg or 162 mg aspirin dose. Participation was terminated before completion of the study.
incomplete platelet inhibition measured by urinary TBx2
Outcome measures
Outcome data not reported
Adverse Events
81 mg Daily Aspirin Dose
162mg Daily Aspirin Dose
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place